Study on efficacy of sage in the treatment of hyperlipidemic patients

Study on Efficacy of Salvia officinalis (L.) Leaves Extract in Treatment of Hyperlipidemic Patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138805132288N1

Enrollment

Registered

2009-11-15

Start date

2009-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia. Hyperlipidemia, unspecified

Interventions

Intervention 1: one placebo capsule is administered to another group of about 30 patients every 8 hours for 1 month. Intervention 2: Sage leaves extract is administered to a group of about 30 patients

Placebo

Treatment - Drugs

one placebo capsule is administered to another group of about 30 patients every 8 hours for 1 month

Sage leaves extract is administered to a group of about 30 patients at the dose of one 500 mg capsule every 8 hours for 1 month.

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients aged 20 to 60 years, patients with serum cholesterol level above 240 mg/dl, patients with serum triglyceride level above 200 mg/dl, patients recently diagnosed as hyperlipidemic, literate patients. Exclusion criteria: patients with serum cholesterol or triglyceride levels above 300 mg/dl, patients with cardiac, renal, hepatic, hematological diseases, hypothyroidism, diabetes, tachycardia, vertigo and seizure, patients with a history of gallstones or gall bladder surgery, patients using estrogen, steroid, beta-blocker and thiazide, pregnant women, women planning pregnancy, breast-feeding women.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decrease of the blood serum cholesterol level in patients. Timepoint: 1 month. Method of measurement: Medical laboratory (kit).;Decrease of the blood serum triglyceride level in patients. Timepoint: 1 month. Method of measurement: Medical laboratory (kit).	—

Secondary

Measure	Time frame
Decrease of the blood serum LDL cholesterol level in patients. Timepoint: 1 month. Method of measurement: Medical laboratory (kit).;Dcrease of the blood serum VLDL lipoprotein level in patients. Timepoint: 1 month. Method of measurement: Medical laboratory (kit).;Increase of the blood serum HDL cholesterol level in patients. Timepoint: 1 month. Method of measurement: Medical laboratory (kit).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Saeed Kianbakht

Institute of Medicinal Plants affiliated with the ACECR

kianbakht@imp.ac.ir, skianbakht@gmail.com+98 26 1476 4010

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026